valsartan/​levamlodipine (SYH-9056) / CSPC Pharma - LARVOL DELTA

CSPC PHARMA…announced that the marketing authorization application for Valsartan and Levamlodipine Besylate Tablets (SYH9056 Tablet) developed by the Group has been accepted by the National Medical Products Administration (NMPA). (iis.aastocks.com) - "The indicated use for this application is for the treatment of mild to moderate essential hypertension that cannot be effectively controlled by monotherapy."

China approval • Hypertension

A Phase III Clinical Trial Evaluating the Efficacy and Safety of Valsartan/Levamlodipine (SYH9056) Tablets In Hypertensive Patients (clinicaltrials.gov) - P3 | N=606 | Not yet recruiting | Sponsor: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Monotherapy • New P3 trial • Cardiovascular • Hypertension